<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584112</url>
  </required_header>
  <id_info>
    <org_study_id>CO42177</org_study_id>
    <secondary_id>2020-000531-47</secondary_id>
    <nct_id>NCT04584112</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer</brief_title>
  <official_title>A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of&#xD;
      tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic&#xD;
      and early triple-negative breast cancer (TNBC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (Cohort B)</measure>
    <time_frame>Up to approximately 21 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed Objective Response Rate ORR (Cohort A)</measure>
    <time_frame>Up to approximately 21 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (Cohort A)</measure>
    <time_frame>Up to approximately 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (Cohort A)</measure>
    <time_frame>Up to approximately 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (Cohort A)</measure>
    <time_frame>Up to approximately 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Cohort A)</measure>
    <time_frame>Up to approximately 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Tiragolumab</measure>
    <time_frame>Cohort A: Day 1 of Cycles (cycle=28 days) 1, 2, 3, 4, 8, 12, and 16 and at TD visit from start of treatment up to approximately 17 months; Cohort B: Day 1 of Cycles (cycle=28 days) 1-5 and at TD visit from start of treatment up to approximately 5 months</time_frame>
    <description>TD visit: treatment discontinuation visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Atezolizumab</measure>
    <time_frame>Cohort A: Day 1 of Cycles (cycle=28 days) 1, 2, 3, 4, 8, 12, and 16 and at TD visit from start of treatment up to approximately 17 months; Cohort B: Day 1 of Cycles (cycle=28 days) 1-5 and at TD visit from start of treatment up to approximately 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Nab-paclitaxel (Cohort B)</measure>
    <time_frame>Cohort B: Day 1 of Cycles (cycle=28 days) 1-5 and at TD visit from start of treatment up to approximately 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Carboplatin (Cohort B)</measure>
    <time_frame>Cohort B: Day 1 of Cycles (cycle=28 days) 1-5 and at TD visit from start of treatment up to approximately 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Doxorubicin (Cohort B)</measure>
    <time_frame>Cohort B: Day 1 of Cycles (cycle=28 days) 1-5 and at TD visit from start of treatment up to approximately 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Cyclophosphamide (Cohort B)</measure>
    <time_frame>Cohort B: Day 1 of Cycles (cycle=28 days) 1-5 and at TD visit from start of treatment up to approximately 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab</measure>
    <time_frame>Cohort A: Day 1 of Cycles (cycle=28 days) 1, 2, 3, 4, 8, 12, and 16 and at TD visit from start of treatment up to approximately 17 months; Cohort B: Day 1 of Cycles (cycle=28 days) 1-5 and at TD visit from start of treatment up to approximately 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ADAs to Atezolizumab</measure>
    <time_frame>Cohort A: Day 1 of Cycles (cycle=28 days) 1, 2, 3, 4, 8, 12, and 16 and at TD visit from start of treatment up to approximately 17 months; Cohort B: Day 1 of Cycles (cycle=28 days) 1-5 and at TD visit from start of treatment up to approximately 5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with first-line metastatic TNBC will receive tiragolumab and atezolizumab on Day 1 of every 28-day cycle plus nab-paclitaxel on Days 1, 8, and 15 of every 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab every 2 weeks (Q2W) in combination with nab-paclitaxel weekly (QW) and carboplatin every 3 weeks (Q3W) for four cycles, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for four doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participantswith early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab Q2W in combination with nab-paclitaxel QW for 12 weeks, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with G-CSF (filgrastim or pegfilgrastim) or GM-CSF support for four doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiragolumab</intervention_name>
    <description>Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.</description>
    <arm_group_label>Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.</description>
    <arm_group_label>Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel 100 milligrams per square meter (mg/m^2) administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.</description>
    <arm_group_label>Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiragolumab</intervention_name>
    <description>Tiragolumab 420 mg administered by IV infusion Q2W.</description>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC</arm_group_label>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 840 mg administered by IV infusion Q2W.</description>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC</arm_group_label>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel 125 mg/m^2 administered by IV infusion QW.</description>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC</arm_group_label>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin (area under the concentration-time curve [AUC]: 5 milligrams per milliliter per minute [mg/mL/min]) administered by IV infusion Q3W.</description>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 60 mg/m^2 Q2W administered by IV infusion.</description>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC</arm_group_label>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC</arm_group_label>
    <other_name>Lipodox, Doxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 600 mg/m^2 Q2W administered by IV infusion.</description>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC</arm_group_label>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte colony-stimulating factor (G-CSF)</intervention_name>
    <description>G-CSF support for four doses.</description>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC</arm_group_label>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC</arm_group_label>
    <other_name>filgrastim, pegfilgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-macrophage colony-stimulating factor (GM-CSF)</intervention_name>
    <description>GM-CSF support for four doses.</description>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC</arm_group_label>
    <arm_group_label>Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Cohort A:&#xD;
&#xD;
          -  Metastatic or locally advanced unresectable, histologically documented TNBC&#xD;
             characterized by absence of human epidermal growth factor 2 (HER2), estrogen receptor&#xD;
             (ER), and progesterone receptor (PR) expression&#xD;
&#xD;
          -  Only patients with metastatic TNBC tumors that are centrally tested and found to be&#xD;
             programmed death-ligand 1 (PD-L1) positive will be enrolled&#xD;
&#xD;
          -  No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or&#xD;
             metastatic TNBC&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0 or 1&#xD;
&#xD;
          -  Measurable disease, as assessed by the investigator according to RECIST v1.1&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
        Cohort B:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Histologically documented TNBC (negative HER2, ER, and PR status)&#xD;
&#xD;
          -  Confirmed tumor PD-L1 evaluation as documented through central testing of a&#xD;
             representative tumor tissue specimen&#xD;
&#xD;
          -  Primary breast tumor size of greater than (&gt;) 2 centimeters (cm) by at least one&#xD;
             radiographic or clinical measurement&#xD;
&#xD;
          -  Stage at presentation: cT2-cT4, cN0-cN3, cM0&#xD;
&#xD;
          -  Baseline left ventricular ejection fraction (LVEF) greater than or equal to (&gt;/=) 53&#xD;
             percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA)&#xD;
             scans&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Cohort A:&#xD;
&#xD;
          -  Formalin-fixed, paraffin-embedded (FFPE) tumor tissue that is PD-L1 negative, as&#xD;
             determined on the SP142 PD-L1 immunohistochemistry assay, with positivity defined as&#xD;
             immune cells greater than or equal to (&gt;/=) 1%&#xD;
&#xD;
          -  Spinal cord compression not definitively treated with surgery and/or radiation or&#xD;
             previously diagnosed and treated spinal cord compression without evidence that disease&#xD;
             has been clinically stable for &gt;2 weeks prior to initiation of study treatment&#xD;
&#xD;
          -  Known central nervous system (CNS) disease, except for treated asymptomatic CNS&#xD;
             metastases&#xD;
&#xD;
          -  Leptomeningeal disease&#xD;
&#xD;
        Cohort B:&#xD;
&#xD;
          -  History of invasive breast cancer&#xD;
&#xD;
          -  Stage IV (metastatic) breast cancer&#xD;
&#xD;
          -  Prior systemic therapy for treatment and prevention of breast cancer&#xD;
&#xD;
          -  Previous therapy with anthracyclines, platinum, or taxanes for any malignancy&#xD;
&#xD;
          -  Synchronous, bilateral invasive breast cancer&#xD;
&#xD;
          -  Cardiopulmonary dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: CO42177 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Magee-Woman's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Onc., PLLC - SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mater Hospital; Cancer Services</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit</name>
      <address>
        <city>Bull Creek</city>
        <state>Western Australia</state>
        <zip>6149</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Rafael - HSR</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Araujo Jorge; Departamento de Ginecologia E Mama</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74605-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sírio-Libanês</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01317-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irccs Centro Di Riferimento Oncologico (CRO)</name>
      <address>
        <city>Aviano</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <state>Arhangelsk</state>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBIH &quot;Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM&quot;</name>
      <address>
        <city>Moskva</city>
        <state>Moskovskaja Oblast</state>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blokhin Cancer Research Center; Combined Treatment</name>
      <address>
        <city>Moskva</city>
        <state>Moskovskaja Oblast</state>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>LA Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena; Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia; Servicio de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital; Surgery</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan Uni Hospital; General Surgery</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

